CliffBio
small molecule

TIROSINT

LEVOTHYROXINE SODIUM

Loss of exclusivitySeptember 2044latest FDA-listed patent expiry
CompanyIBSA Institut Biochimique →See this company's full patent-cliff portfolio

Drug detail

Brand nameTIROSINT
Active ingredientLEVOTHYROXINE SODIUM
Strength0.0375MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2022
Marketing statusRX

Listed patents

PatentExpiresType
12564565September 2044product

More from IBSA Institut Biochimique

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TIROSINT patent cliff — loss of exclusivity September 2044 | CliffBio